Literature DB >> 7854336

A transformed murine Leydig cell line expresses the ETA receptor subtype.

A Ergul1, M K Glassberg, M E Freeman, D Puett.   

Abstract

We recently demonstrated that transformed murine Leydig cells (MA-10) responded to endothelin-1 (ET-1) via increased steroidogenesis. This study addresses the endothelin receptor subtype present on this cell line and whether or not the cells produce ET-1. The expression of the preproendothelin-1 (PPET-1) gene was investigated by Northern blot analysis, and PPET-1 mRNA was found to be < 0.2% of that present in pulmonary endothelial cells. The medium from MA-10 cells, maintained under serum-free conditions, was analyzed by radio-immunoassay to determine immunoreactive-ET-1 production and ET-1 levels were found to be below the sensitivity of the assay (< 10 pg/ml). The data from competitive binding experiments with [125I]ET-1 and unlabeled ET-1, ET-3 and receptor subtype selective ligands yielded a single class of high affinity binding sites with ETA receptor subtype characteristics. The results of this study demonstrate that MA-10 cells possess the ETA receptor subtype but do not produce significant quantities of ET-1 under basal conditions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7854336     DOI: 10.1007/bf00931610

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  22 in total

1.  Properties and localization of endothelin-1-specific receptors in rat testicles.

Authors:  H Sakaguchi; M Kozuka; S Hirose; T Ito; H Hagiwara
Journal:  Am J Physiol       Date:  1992-07

2.  Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor.

Authors:  M Ihara; K Noguchi; T Saeki; T Fukuroda; S Tsuchida; S Kimura; T Fukami; K Ishikawa; M Nishikibe; M Yano
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

3.  Production of endothelin in human cancer cell lines.

Authors:  M Kusuhara; K Yamaguchi; K Nagasaki; C Hayashi; A Suzaki; S Hori; S Handa; Y Nakamura; K Abe
Journal:  Cancer Res       Date:  1990-06-01       Impact factor: 12.701

4.  Endothelin stimulates phospholipase C, Na+/H+ exchange, c-fos expression, and mitogenesis in rat mesangial cells.

Authors:  M S Simonson; S Wann; P Mené; G R Dubyak; M Kester; Y Nakazato; J R Sedor; M J Dunn
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

5.  Endothelin, a novel vasoconstrictor peptide, as potent bronchoconstrictor.

Authors:  Y Uchida; H Ninomiya; M Saotome; A Nomura; M Ohtsuka; M Yanagisawa; K Goto; T Masaki; S Hasegawa
Journal:  Eur J Pharmacol       Date:  1988-09-13       Impact factor: 4.432

6.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells.

Authors:  M Yanagisawa; H Kurihara; S Kimura; Y Tomobe; M Kobayashi; Y Mitsui; Y Yazaki; K Goto; T Masaki
Journal:  Nature       Date:  1988-03-31       Impact factor: 49.962

7.  Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells.

Authors:  I Komuro; H Kurihara; T Sugiyama; M Yoshizumi; F Takaku; Y Yazaki
Journal:  FEBS Lett       Date:  1988-10-10       Impact factor: 4.124

Review 8.  Endothelins: homeostatic and compensatory actions in the circulatory and endocrine systems.

Authors:  T Masaki
Journal:  Endocr Rev       Date:  1993-06       Impact factor: 19.871

9.  Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines.

Authors:  M Shichiri; Y Hirata; T Nakajima; K Ando; T Imai; M Yanagisawa; T Masaki; F Marumo
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

10.  Sarafotoxin S6c: an agonist which distinguishes between endothelin receptor subtypes.

Authors:  D L Williams; K L Jones; D J Pettibone; E V Lis; B V Clineschmidt
Journal:  Biochem Biophys Res Commun       Date:  1991-03-15       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.